Discovery of novel virus neutralizing antibodies

New AntibodiesThe identification of novel antibodies to neutralize the virus is one of our approaches to fight COVID-19. In particular, we aim to discover an antibody against the SARS-CoV-2 spike protein by building on knowledge about the existing structure of SARS-CoV-2 and learnings from previous SARS antibody generations. The so-called spike protein of 2019-nCoV is used by the virus to dock to human cells. By targeting the protein, we aim to prevent the infection. 

 

More related content

COVID-19

COVID-19

As a company, we consider it our duty to take the best possible care of the protection and health of our employees, our patients and society. Boehringer Ingelheim is engaged at various levels of action to contain and cope with the global spread of COVID-19. 

Read more on COVID-19

COVID-19

Protecting Our Employees
Read more on Protecting Our Employees

COVID-19

Animal Health Customers
Read more on Animal Health Customers

COVID-19

Protecting Humans & Animals
Read more on Protecting Humans & Animals

COVID-19

Healthcare Professionals
Read more on Healthcare Professionals